The First AI Formulated Drug Reaches the Clinic: Inside Quotient Sciences' Phase I Milestone and Pharma's 2026 Inflection
Quotient Sciences, working with Intrepid Labs' machine learning, has begun what is reported as the first human clinical study of an AI designed drug formulation, after MHRA approval in the UK. Chris and Laura unpack the crucial difference between an AI designed molecule and an AI designed formulation, and what it means that there are now 200+ AI originated drug programs in clinical development. They dig into the eye catching 90 percent Phase I success claim, compressed 12 to 18 month timelines, the $2.6 billion cost problem, Insilico Medicine's idiopathic pulmonary fibrosis candidate, and the roughly 60 percent odds of a first AI originated drug approval landing in 2026 or 2027.
Hosted by Chris and Laura.
The DX Today Podcast brings you daily deep dives into the most consequential stories in the AI ecosystem.
Podden och tillhörande omslagsbild på den här sidan tillhör
Rick Spair. Innehållet i podden är skapat av Rick Spair och inte av,
eller tillsammans med, Poddtoppen.
